CVI Holdings LLC acquired a new position in shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 80,758 shares of the company’s stock, valued at approximately $58,000. Sonoma Pharmaceuticals makes up 0.1% of CVI Holdings LLC’s investment portfolio, making the stock its 20th biggest holding.
NASDAQ:SNOA opened at $1.00 on Friday. Sonoma Pharmaceuticals Inc has a fifty-two week low of $0.64 and a fifty-two week high of $4.80. The stock has a market cap of $11.97 million, a price-to-earnings ratio of -0.32 and a beta of 1.10.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its earnings results on Thursday, February 14th. The company reported ($0.26) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.08. Sonoma Pharmaceuticals had a negative return on equity of 102.49% and a negative net margin of 73.12%. The company had revenue of $5.28 million for the quarter, compared to analysts’ expectations of $5.21 million. As a group, equities research analysts forecast that Sonoma Pharmaceuticals Inc will post -1.21 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This report was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://sportsperspectives.com/2019/03/17/cvi-holdings-llc-acquires-shares-of-80758-sonoma-pharmaceuticals-inc-snoa.html.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions.
Recommended Story: What is a Futures Contract?
Want to see what other hedge funds are holding SNOA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sonoma Pharmaceuticals Inc (NASDAQ:SNOA).
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.